Polyceutix
Polyceutix is developing AASTY-TLR, an injectable immunomodulatory copolymer designed to cure muscle-invasive bladder cancer by solubilizing tumor lipid bilayers and membrane proteins into polymer-lipid particles. This process releases cancer neoantigens in a form readily taken up by immune cells, while an attached TLR agonist amplifies the resulting adaptive anti-tumor response. The compound is administered directly into tumors, aiming to trigger a potent, tumor-specific immune reaction while sparing healthy tissue.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
- New Materials
Funding
Founders
Founder details are not available yet.
Product
Problem
Muscle-invasive bladder cancer remains difficult to treat effectively, with current therapeutic options often failing to trigger a durable immune response against the tumor. Conventional immunotherapies frequently lack tumor specificity, leading to limited efficacy or systemic toxicity.
Solution
Polyceutix aims to cure muscle-invasive bladder cancer using AASTY-TLR, a novel immunomodulatory compound invented at the interface of materials science and immunology. AASTY-TLR is a copolymer injected directly into tumors, where it solubilizes lipid bilayers and membrane proteins therein into polymer-lipid particles. This process releases cancer neoantigens in solubilized form, which immune cells uptake, triggering a powerful adaptive anti-tumor response. The TLR agonist attached to each copolymer further amplifies immune activation, creating a potent therapeutic effect designed to eliminate the tumor while sparing healthy tissue.
Target Audience
Primary customers are patients with muscle-invasive bladder cancer and the oncology centers and urology departments that treat them, as well as clinical researchers specializing in cancer immunotherapy.
Features
- Injectable copolymer that solubilizes tumor lipid bilayers and membrane proteins into polymer-lipid particles
- Solubilization releases cancer neoantigens in a form readily taken up by immune cells
- Attached TLR agonist amplifies immune activation for a stronger anti-tumor effect
- Designed specifically for localized intratumoral administration in muscle-invasive bladder cancer
- Novel mechanism combining materials science with immunology to trigger adaptive immune responses